Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03249558 · ClinicalTrials.gov registry record · Phase 4
Effect of Combined Morphine and Duloxetine on Chronic Pain
A Phase 4 study, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- Phase 4
- Development phase
- 81
- Enrollment target
NCT03249558: Completed Phase 4 study, sponsored by Massachusetts General Hospital.
NCT03249558 is a Phase 4 study that has completed, run by Massachusetts General Hospital. The registered enrollment target is 81 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03249558, a Phase 4 study, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 81 participants
- Enrollment target
Study Summary
A double-blind, randomized, and placebo-controlled clinical study examining whether duloxetine, a serotonin and norepinephrine reuptake inhibitor (SNRI), could enhance opioid analgesia and reduce overall opioid use. Positive outcomes will help improve the overall effectiveness of clinical opioid therapy and reduce unnecessary opioid dose escalation.
Interventions
- DRUG Placebo
- DRUG Duloxetine
- DRUG Morphine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 81 participants |
| Start Date | 2018-03-12 |
| Est. Completion | 2022-04-05 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03249558
The ClinicalTrials.gov registry entry for NCT03249558 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 81 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT03249558 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03249558 about?
NCT03249558 is a clinical study titled "Effect of Combined Morphine and Duloxetine on Chronic Pain". A double-blind, randomized, and placebo-controlled clinical study examining whether duloxetine, a serotonin and norepinephrine reuptake inhibitor (SNRI), could enhance opioid analgesia and reduce overall opioid use. Positive outcomes will help improve the overall effectiveness of clinical opioid the...
What is the current status of trial NCT03249558?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 81 participants. The study started on 2018-03-12. Estimated completion is 2022-04-05.
What interventions are being tested in trial NCT03249558?
The interventions under investigation include: Placebo (DRUG), Duloxetine (DRUG), Morphine (DRUG).
Who is sponsoring clinical trial NCT03249558?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.